Gang Zhu

Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ.

The Chartered Governance Institute provides governance and compliance services. The company was incorporated by Royal Charter in 1891 and is headquartered in London, the United Kingdom.

Peking University provides post-secondary education services. It offers undergraduate and graduate courses. It provides courses such as basic and applied sciences, social sciences and the humanities, sciences of medicine, management, and education. The company was founded by JiaNai Sun in 1898 and is headquartered in Beijing, China.

Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA.

Jingtian & Gongcheng Law Firm provides legal services. The private company is based in Beijing, China. and has subsidiaries in Hong Kong.

Part of Ernst & Young Global Ltd., Ernst & Young Hua Ming LLP is a Chinese company that provides accounting services. The company is based in Shanghai, China.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Hong Kong Institute of Certified Public Accountants operates under the professional accountant’s ordinance and works in the public interest. It offers CPA qualification programme and promulgating financial reporting, auditing and ethical standards in Hong Kong. The company was founded on January 1, 1973 and is headquartered in Hong Kong.

The Hong Kong Institute of Chartered Secretaries is an independent professional body that promotes the role of its members in formulating and implementing good governance policies. The private company is based in Hong Kong, Hong Kong. It also aims to develop the profession of chartered secretary and chartered governance professional in mainland China. The institute was established in 1949 as an association of members of the Chartered Governance Institute and gained local status in 1994. It has more than 6,000 members and 3,200 students.

The Association of Chartered Certified Accountants (ACCA) is a professional body for accountants. The non-profit company is based in Glasgow, UK, and has subsidiaries in Mauritius, United Kingdom, and Hong Kong. The British company offers a program called ALP-C, which approves learning materials from high-quality content providers to support studying towards ACCA's qualification. The role of the CFO is evolving beyond finance to include reporting on value-centric aspects of their operations, as companies move towards sustainable practices. The CEO of the company is Helen Joanna Brand.

Part of Orient Securities Co., Ltd., Orient Securities Investment Banking Co., Ltd. is a Chinese company that provides securities brokerage services. The company is based in Shanghai, China. The company was founded in 2012. Ji Ma has been the CEO of the company since 2012. Orient Securities Investment Banking Co. was acquired by Orient Securities Co., Ltd. from Citigroup Global Markets Asia Ltd. on April 22, 2020 for $69.43 million.

Jiangsu Yasheng Pharmaceutical Development Co. Ltd. develops and produces pharmaceutical products. It focuses on research and development of structure-based molecule for cancer drugs. The company was founded by Dajun Yang, Ming Guo, and Shaomeng Wang in 2009 and is headquartered in Hong Kong.

Part of Ernst & Young Global Ltd., Ernst & Young (Hong Kong) Ltd. is a Chinese company that provides accounting, assurance, tax, transaction and advisory services. The company is based in Hong Kong, Hong Kong.

Part of Simon Property Group, Inc., Taubman Asia Management Ltd. provides real estate services. The company is based in Hong Kong, Hong Kong.

FinUp Finance Technology Group (Holding) Ltd. operates as tech-enabled inclusive finance platform in China with a focus on marketplace lending. It offers personal credit services including POS installment services and automobile financing services. The company alos focuses on serving the personal financial needs of individuals who are currently underserved by traditional financial institutions. The company was founded by Zhang Hui, Dong Qi, Zhang Fan and Yang Fan on December 9, 2014 and is headquartered in Beijing, China.

Tasly Biopharmaceuticals Co., Ltd. is a biopharmaceutical company, which engages in research & development, manufacturing, sales and marketing of proprietary biological products. It focuses on therapeutic areas of cardiovascular diseases, oncology and autoimmune, and alimentary tract and metabolism. The company was founded by Lv Xinbo on October 29, 2001 and is headquartered in Shanghai, China.

Wai Fong Holdings Ltd. engages in the provision of infrastructure civil engineering and general building services. It operates through the following segments: Construction Services, Infrastructure Civil Engineering Projects, General Building Works, and Project Management Services. The Construction Services segment operates as RC subcontractor for bridges and rails. The Infrastructure Civil Engineering Projects segment includes mass rapid transit, road, tunnel, and drainage works. The General Building Works segment consists of rebar, formwork erection, and concrete works. The Project Management Services segment provides project arrangements with joint venture partners. The company was founded by Seong Choy Chai in 1993 and is headquartered in Singapore.

Macaw Corporate Services Ltd. provides corporate governance, ongoing regulatory compliance, company secretarial, and accounting services for small and medium-sized enterprises and listed companies. The company was founded by Cheung Ki Wong on June 6, 2017 and is headquartered in Hong Kong.

Part of Ascentage Pharma Group International Co., Ltd., Suzhou Ascentage Pharma Co., Ltd. is a pharmaceutical company. Suzhou Ascentage Pharma Co., Ltd. is based in Suzhou, China. The Chinese company was founded in 2016 by Guang Feng Wang. The CEO is Da Jan Yang.

Part of Ascentage Pharma Group International Co., Ltd., Ascentage Pharma Group Corp. Ltd. is a Chinese biopharmaceutical company. The company is based in Hong Kong, Hong Kong. The company was founded by Shao Meng Wang.

SDIC Innovation Investment Management Co. Ltd. is a company headquartered in Beijing, China. The firm acts as an alternative investment manager. It was founded in 2009.